...
首页> 外文期刊>Expert review of hematology >Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199
【24h】

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199

机译:急性髓性白血病的靶向疗法:专注于FLT3抑制剂和ABT 199

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Acute myeloid leukemia (AML) remains a therapeutic challenge. Despite ongoing research, the standard therapy for AML has not changed significantly in the past four decades. With the identification of cytogenetic and molecular abnormalities, several promising therapeutic agents are currently being investigated. FLT3 mutation is a well-recognized target seen in 30% of the cytogenetically normal AML. More recently, the BCL2 family of anti-apoptotic proteins have also generated great interest as a therapeutic target.Areas covered: This review will cover the role of FLT3 inhibitors in AML, discussing trials in relapsed/refractory AML and in the frontline setting, including the young and elderly patient population. Toxicities and potential mechanism of resistance will also be covered. In addition, most current studies demonstrating the role of BCL-2 inhibitors namely ABT-199/venetoclax in AML will also be discussed.Expert commentary: AML is one of the most heterogeneous group of hematological malignancies. It remains a therapeutic challenge with limited therapeutic progress despite ongoing research. With the identification of different mutations in AML, several drugs are being evaluated in clinical trials. Targeted agents such as FLT3 inhibitors and BH3 mimetics so far have shown promising results in terms of response and toxicity profile.
机译:简介:急性髓性白血病(AML)仍然是治疗性挑战。尽管采取了持续的研究,但过去四十年的AML的标准治疗尚未显着变化。随着细胞遗传学和分子异常的鉴定,目前正在研究几种有前途的治疗剂。 FLT3突变是一种识别的靶标,在30%的细胞藻体正常AML中观察。最近,BCL2抗凋亡蛋白家族也为治疗目标产生了极大的兴趣。覆盖:本综述将涵盖FLT3抑制剂在AML中的作用,讨论复发/难治AML和前线设置中的试验,包括年轻人和老年人的患者人口。还将涵盖毒性和潜在抵抗机制。此外,还将讨论展示BCL-2抑制剂作用的大多数研究ABT-199 / venetoclax在AML中.Expert评论:AML是最异丙族恶性肿瘤组之一。尽管持续研究,但仍然是治疗进展有限的治疗挑战。随着AML中的不同突变的鉴定,在临床试验中评估了几种药物。迄今为止,FLT3抑制剂和BH3模拟物等靶向剂表明了对响应和毒性概况的有希望的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号